By combining gene expression profile, copy number alterations, and miRNA expression profiles as available from published datasets of BC human tissue samples, we have recently identified in silico, a 4-miRNA signature (Hsa-miR-567, Hsa-miR-139-5p, Hsa-miR-320d, Hsa-Let-7c) and a 4-target mRNA signature (KPNA4, H2AFV, FOXM1, DDX19A) that are able to accurately classify BC patients into G1-like and G3-like groups, thus improving BC grade definition and confirming the existence of only two prognostic groups [5]. The gene discussed is H2AZ2; the disease is breast cancer.